Officials with Henry Ford Health announced on Thursday that their study has shown that hydroxychloroquine “significantly” decreases the death rate of COVID-19 sufferers. They came to their conclusion after analyzing 2,541 patients who were confined in their hospital system from March 10 and May 2. They found that 13 percent of patients treated with hydroxychloroquine died while 26 percent of patients who did not receive the miracle drug died.
“As doctors and scientists, we look to the data for insight,” said Steven Kalkanis, CEO of the Henry Ford Medical Group. “And the data here is clear that there was a benefit to using the drug as a treatment for sick, hospitalized patients.”
There were also no heart-related problems that patients suffered from being treated with the drug in the study. Dr. Marcus Zervos noted that hydroxychloroquine is more effective when patients are treated with the drug early after their diagnosis with COVID-19.
“We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring,” said Zervos, who works as division head of infectious disease for Henry Ford Health. Zervos conducted the study with epidemiologist Dr. Samia Arshad.